Doctors test direct brain infusion to fight recurrent childhood cancers
NCT ID NCT06466798
Summary
This study aimed to test the safety of delivering cancer drugs directly into a fluid-filled space in the brain (the fourth ventricle) for people with recurrent brain tumors like medulloblastoma and ependymoma. It planned to give an immunotherapy drug (nivolumab) combined with another chemotherapy drug. The goal was to see if this local delivery method was safe and could help control the cancer. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT EPENDYMOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.